COIOSDeep risk insights through multi-disciplinary research across the globe
Modern glass building with green trees and cloudy sky
Item new Peer-reviewed Added

Kidney disease progressed less often on a GLP-1 drug plus SGLT2 inhibitor

Among 32,448 matched adults with chronic kidney disease, those adding a GLP-1 drug to an SGLT2 inhibitor had 0.70 times the rate of kidney disease progression over a median year.

A retrospective TriNetX cohort matched 16,224 adults with chronic kidney disease on an SGLT2 inhibitor against 16,224 who later added a GLP-1 drug. Over a median 12 months, the combination carried 0.70 times the rate of kidney disease progression and 0.55 times the rate of death. Gastrointestinal symptoms, genital infections and retinopathy progression were more common on the combination, while volume depletion and acute kidney injury were less common.

Why it is interesting: Combination therapy is compared with an SGLT2 inhibitor alone, although who started the second drug was not random.

Source
Diabetes, Obesity and Metabolism, 27 September 2026
Paper
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
Authors
Salim H, Qureshi S, Gulsin GS, Khan HR, Waqas SA, McCann GP et al.
DOI
10.1111/dom.71375
Type
Peer-reviewed article
Design
Retrospective propensity-matched cohort, TriNetX global network, 32,448 adults with CKD, 2020-2023, median 12 months follow-up
Verdict
New finding
Driver
Obesity, diabetes and GLP-1
Free full text
Free to read at the publisher
Abstract — the authors' own words, CC BY

Background

Individually, sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP-1RA and SGLT2i therapy in this population remains limited. Methods

We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, including adults with CKD treated with SGLT2i alone or SGLT2i with subsequent initiation of GLP-1RA between June 2020 and December 2023. Propensity score matching (1:1) adjusted for demographics, comorbidities, medications, and laboratory values. The primary outcome was major adverse kidney events (MAKE); secondary outcomes included all-cause mortality and major adverse cardiovascular events (MACE). Time-to-event analyses were performed using Cox proportional hazards models. Results

Among 112 596 patients with CKD, 16460 received SGLT2i and GLP-1RA combination therapy, and 96 136 received SGLT2i monotherapy. The matched cohort included 32 448 patients (16 224 per group). Over a median follow-up of 12 months, the addition of a GLP-1RA was associated with lower rates of the primary outcome of MAKE (HR 0.70; 95% CI 0.65-0.74; p Conclusions

In this real-world CKD cohort, GLP-1RA added to SGLT2i therapy was associated with substantial incremental reductions in kidney disease progression and cardiovascular events. These findings suggest an additive cardiorenal benefit, particularly in patients with obesity, supporting the evaluation of combination therapy in future randomised trials.

Other drivers in Health today